Versartis Inc. (Nasdaq: VSAR) reported disappointing results from a VELOCITY Phase 3 clinical trial of somavaratan to treat pediatric growth hormone deficiency. Shares of the biopharmaceutical collapsed $18.93 to close at $2.67.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|